Remove Clinical Trials Remove Download Remove Epilepsy Remove Patients
article thumbnail

CBD Market Report

Project CBD

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. Epilepsy Behav.

CBD 144
article thumbnail

Use of Cannabis-based medicinal products: NICE guidelines

Cannabis Law Report

Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. After the 4-week trial, continue THC:CBD spray if the person has had at least a 20% reduction in spasticity-related symptoms on a 0 to 10 patient-reported numeric rating scale. Recommendations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medical Cannabis Company Sunshine Coast Tikun Oceana, formerly known as Medifarm Calls In The Administrators

Cannabis Law Report

“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

article thumbnail

NORML 2019 Legislative Report

Cannabis Law Report

Since 2014, annual appropriations bills have been amended to include a spending restriction to prevent the Department of Justice from enforcing the federal prohibition of marijuana against state-legal medical cannabis programs, businesses, and patients. Included in the final FY 2020 spending package). It took immediate effect upon passage.